Table 2.

Univariate analysis of nonresponse to bevacizumab combination therapy based on AGT promoter methylation in the training cohort. OR, Odds ratio; CI, Confidence interval.

AGT promoter methylation	Nonresponse
Twofold decrease	OR (95% CI)	P‐value	AUC
CpG site 1	2.93 (1.44–5.94)	0.003	0.72
CpG site 2	2.73 (1.28–5.83)	0.01	0.69
CpG site 3	2.18 (1.17–4.04)	0.01	0.67
CpG site 4	2.04 (1.14–3.66)	0.02	0.66
Mean CpG sites 1–4	3.01 (1.41–6.44)	0.004	0.70